Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tirzepatide for Weight Reduction in Chinese Adults With Obesity
Lin Zhao, Zhifeng Cheng, Yibing Lu, et al.
JAMA (2024)
Open Access | Times Cited: 25

Showing 25 citing articles:

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
Francisco Westermeier, Enrique Z. Fisman
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
Takashi Kadowaki, Arihiro Kiyosue, Tomotaka Shingaki, et al.
The Lancet Diabetes & Endocrinology (2025)
Closed Access | Times Cited: 1
Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
Yue Yin, Minghan Zhang, Qiuyu Cao, et al.
Journal of Diabetes (2025) Vol. 17, Iss. 4
Open Access | Times Cited: 1
Frontier Exploration of Obesity Treatment: A Combination of Drugs, Surgery and Lifestyle Intervention
雨晴 何
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 691-697
Closed Access
GLP-1RA: New Hope in Obesity Therapy
Danfeng Zhang, Hongyun Lu
Journal of Biosciences and Medicines (2025) Vol. 13, Iss. 02, pp. 465-479
Open Access
Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis
A. B. M. Kamrul‐Hasan, Joseph M. Pappachan, Deep Dutta, et al.
World Journal of Diabetes (2025) Vol. 16, Iss. 4
Closed Access
Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
Mohammed Sallam, Johan Snygg, Sara El Ghandour, et al.
Obesities (2025) Vol. 5, Iss. 2, pp. 26-26
Open Access
The Effect of Tirzepatide on Body Composition in People with Overweight and Obesity: A Systematic Review of Randomized, Controlled Studies
Vincenzo Rochira, Carla Greco, Stefano Boni, et al.
Diseases (2024) Vol. 12, Iss. 9, pp. 204-204
Open Access | Times Cited: 3
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials
Zeyu Xie, Guimei Zheng, Zhuoru Liang, et al.
Metabolism (2024) Vol. 161, pp. 156038-156038
Closed Access | Times Cited: 3
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Areeba Fareed, Laura Ghanem, Rayyan Vaid, et al.
Endocrine Practice (2024)
Closed Access | Times Cited: 2
Drug treatment for MASLD: Progress and direction
Da Zhou, Jian‐Gao Fan
Chinese Medical Journal (2024)
Open Access | Times Cited: 2
Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis
Lisheng Liu, Zhiqi Li, Wenxiu Ye, et al.
EClinicalMedicine (2024) Vol. 79, pp. 103020-103020
Closed Access | Times Cited: 2
Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?
Yuchen Jiang, Huijuan Zhu, Fengying Gong
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 1
Tirzepatide for overweight and obesity management
Malak Hamza, Dimitris Papamargaritis, Melanie J. Davies
Expert Opinion on Pharmacotherapy (2024), pp. 1-19
Open Access | Times Cited: 1
Clinical practice guidelines for the management of hypertension in China

Chinese Medical Journal (2024)
Open Access | Times Cited: 1
Efficacy of Tirzepatide for Weight Loss in China
Frank Qian, Frank B. Hu
JAMA (2024) Vol. 332, Iss. 7, pp. 538-538
Closed Access
Tirzepatide—New Evidence for the Treatment of Obesity From China
Weiping Jia, Jianzhong Xiao, Juliana C.N. Chan
JAMA (2024) Vol. 332, Iss. 7, pp. 536-536
Closed Access
Errors in Figure, Results, and End Matter

JAMA (2024) Vol. 332, Iss. 7, pp. 595-595
Open Access
Effectiveness of an Intelligent and Integrated Older Care Model on Quality of Life among Home-dwelling Older Adults: A Randomized Controlled Trial (Preprint)
Rongrong Guo, Jiwen Zhang, Fangyu Yang, et al.
(2024)
Open Access
Are GLP-1 drugs really for everybody?

Nature Medicine (2024) Vol. 30, Iss. 11, pp. 3029-3029
Closed Access
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
Chen Zhao, Wenqiang Li, Zhiping Deng
JAMA (2024)
Closed Access
Tirzepatide for Weight Reduction in Chinese Adults With Obesity—Reply
Lin Zhao, M Kellis
JAMA (2024)
Closed Access
Tirzepatide in Treating Metabolic Disorders
Shulin Wei, Suowen Xu
International Journal of Drug Discovery and Pharmacology (2024), pp. 100023-100023
Open Access
Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis
A B Kamrul-Hasan, Sunetra Mondal, Deep Dutta, et al.
Obesity Science & Practice (2024) Vol. 10, Iss. 6
Open Access
Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis
A B Kamrul-Hasan, Shinjan Patra, Deep Dutta, et al.
World Journal of Diabetes (2024) Vol. 16, Iss. 2
Closed Access
Page 1

Scroll to top